Jennifer Fried
Venture Partner & Lead Investor : FemTech Fund 1 and 2 @ Portfolia
Chicago, United States
Jennifer Fried is a seed investor at Portfolia in Chicago focused on Health Care and Medical Device. Jennifer Fried is the CEO & Co-Founder of ExplORer Surgical .
- Total investments:
- 12
- Last investment:
- Lead investor:
- 50%
Last updated:
For AI agents: llms.txt
Industries Jennifer Fried invests in
Stages Jennifer Fried invests in
Countries Jennifer Fried invests in
Round sizes
Round size
- Seed
- $2.1M–$4.3M
Investment Focus
Industry
- Health Care 5 (42%)
- Medical Device 4 (33%)
- Women's 3 (25%)
- Medical 2 (17%)
- Wellness 2 (17%)
Stage
- Seed 3 (25%)
- Series A 3 (25%)
- Series B 1 (8%)
- Series C 1 (8%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Nest Collaborative
|
Nest Collaborative is a provider of on-demand lactation counseling services intended to offer a collection of international board certified lactation consultants who conduct online, video appointments to help guide moms through the breastfeeding process. The company's services are offered via an online platform that offers reimbursed maternal,neonatal and lactation counseling services, enabling women to avail safe, convenient and affordable access to quality pediatric care, at home. | $4.3M / Seed / Mar 15, 2022 | |
Proov
|
Proov offers patented at home testing systems - including the only FDA cleared at-home test to measure progesterone metabolite PdG - to help women understand and act on their hormones.When used with the Proov Insight app, Proov's easy, at-home pee tests provide a science-backed fertility coach right in your hand. First, a woman can measureall of the menstrual hormones daily with Proov tests, then snap a photo of each test within the Insight app. Then, a woman can follow the in-app prompts throughout her cycle to understand ovulation status, get daily insights and an Ovulation Insights score. Finally, the app generates a personalized action plan to maximize her wellness or develop a fertility strategy. Proov was founded by Amy Beckley, Ph.D, the "infertile scientist," after three years of infertility and seven miscarriages. Amy applied her own science expertise to uncover a luteal phase defect (a problem with ovulation quality). With help from her doctor and a simple supplement, Amy was able to get pregnant with her daughter.Proov is a venture capital backed company and the leader in understanding hormone health on the basis of tracking PdG, a metabolite of progesterone. | $9.7M / Series A / Dec 15, 2021 | |
Willow
|
Willow is a female technology company that develops an in-bra wearable breast pump, replacement parts, breastfeeding essentials, pumping bras, cases and bags, breastfeeding essentials, and more. | $26.8M / Series C / Apr 21, 2021 | |
|
Nest Collaborative
|
Nest Collaborative is a provider of on-demand lactation counseling services intended to offer a collection of international board certified lactation consultants who conduct online, video appointments to help guide moms through the breastfeeding process. The company's services are offered via an online platform that offers reimbursed maternal,neonatal and lactation counseling services, enabling women to avail safe, convenient and affordable access to quality pediatric care, at home. | $2.1M / Seed / Feb 17, 2021 | |
|
Nest Collaborative
|
Nest Collaborative is a provider of on-demand lactation counseling services intended to offer a collection of international board certified lactation consultants who conduct online, video appointments to help guide moms through the breastfeeding process. The company's services are offered via an online platform that offers reimbursed maternal,neonatal and lactation counseling services, enabling women to avail safe, convenient and affordable access to quality pediatric care, at home. | Seed / Feb 12, 2021 | |
Madorra
|
Madorra Their goal is empowering women to live fuller, healthier lives. Madorra is working towards changing the paradigm for treating vaginal dryness, by providing a medical device solution to a problem that has previously only been served by pharmaceuticals. They are focused on giving post-menopausal women and breast cancer survivors the power tochoose the non-hormonal treatment option they want. | Seed / Dec 01, 2020 | |
|
Madorra
|
Madorra Their goal is empowering women to live fuller, healthier lives. Madorra is working towards changing the paradigm for treating vaginal dryness, by providing a medical device solution to a problem that has previously only been served by pharmaceuticals. They are focused on giving post-menopausal women and breast cancer survivors the power tochoose the non-hormonal treatment option they want. | Series A / Dec 01, 2020 | |
Solace Therapeutics
|
Solace Therapeutics is a medical device company that develops and commercializes non-surgical office-based treatments for common bladder disorders, such as stress urinary incontinence (SUI), overactive bladder (OAB), male voiding dysfunction and lower urinary tract symptoms (LUTS). It is dedicated to improving the patient’s quality of life byeliminating side effects typically associated with current drug and surgical therapies.The company offers a technology that is designed to offer patients an office-based therapy that does not require anesthesia or surgery, no lifestyle change required, before or after treatment, and reversible at any time. | Seed / Apr 01, 2020 | |
|
Solace Therapeutics
|
Solace Therapeutics is a medical device company that develops and commercializes non-surgical office-based treatments for common bladder disorders, such as stress urinary incontinence (SUI), overactive bladder (OAB), male voiding dysfunction and lower urinary tract symptoms (LUTS). It is dedicated to improving the patient’s quality of life byeliminating side effects typically associated with current drug and surgical therapies.The company offers a technology that is designed to offer patients an office-based therapy that does not require anesthesia or surgery, no lifestyle change required, before or after treatment, and reversible at any time. | Seed / Apr 01, 2020 | |
|
Solace Therapeutics
|
Solace Therapeutics is a medical device company that develops and commercializes non-surgical office-based treatments for common bladder disorders, such as stress urinary incontinence (SUI), overactive bladder (OAB), male voiding dysfunction and lower urinary tract symptoms (LUTS). It is dedicated to improving the patient’s quality of life byeliminating side effects typically associated with current drug and surgical therapies.The company offers a technology that is designed to offer patients an office-based therapy that does not require anesthesia or surgery, no lifestyle change required, before or after treatment, and reversible at any time. | Series A / Apr 01, 2020 | |
| See all 12 investments → | |||
Co-Investors
About Portfolia
Portfolia connects sophisticated investors and leaders with entrepreneurial companies. Their platform enables users to collaborate with other members and lead investors to evaluate innovative products and teams, join diligence teams, and immerse themselves in the investment process. It is an investment fund designed for women while backinginnovative companies for returns and impact.
Portfolia Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Amber Caska
Investment Committee Member
|
|||
Trish Costello
Founder & CEO
|
|||
Valentina Vitols
Limited Partner
|
|||
|
Abbe Kligerman
Limited Partner
|
|||
Bethann Kassman
Deal Lead
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Featured in Investor Lists
Recommended lists
FAQ
What does Jennifer Fried invest in?
Jennifer Fried invests primarily in Health Care, Medical Device and Women's startups, most often at Seed and Series A stage. Most of the 12 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Jennifer Fried's check size?
Jennifer Fried typically joins rounds of $2.1M–$4.3M at Seed. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Jennifer Fried participates in.
When did Jennifer Fried last invest?
The most recent investment recorded for Jennifer Fried closed in Mar 2022. Shizune tracks 12 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
